A review of nanocarriers for the delivery of small interfering RNA

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7138-7150

  Kesharwani, Prashant ^a   Gajbhiye, Virendra ^a   Jain, Narendra Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Cytotoxicity; Nanocarriers; Polyplex; SiRNA; Transfection

Indexed keywords

BIOLOGICAL BARRIER; MOLECULAR MECHANISM; NANOCARRIERS; NUCLEIC ACID MEDICINES; POLYPLEXES; POTENTIAL APPLICATIONS; RNA INTERFERENCE; SIRNA; SIRNA DELIVERY; SMALL INTERFERING RNA; TARGET SITES; THERAPEUTIC DRUGS; TRANSFECTION;

CYTOTOXICITY; DENDRIMERS; DISEASES; LIPOSOMES;

RNA;

CARBON NANOTUBE; DENDRIMER; LIPOSOME; NANOCARRIER; NANOPARTICLE; SMALL INTERFERING RNA;

NANOTECHNOLOGY; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

ANIMALS; DENDRIMERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; LIPOSOMES; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; NANOTECHNOLOGY; NANOTUBES, CARBON; NEOPLASM TRANSPLANTATION; RNA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84864324577     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.068     Document Type: Review

References (106)

1. Sinden R.R., Pearson C.E., Potaman V.N., Ussery D.W. DNA: structure and function in advances in genome biology 1998, Jai Press Inc, Greenwich, CT, p. 1-141. 1st ed.
2. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409:363-366.
3. Zhang H., Kolb F.A., Jaskiewicz L., Westhof E., Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004, 118:57-68.
4. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007, 76:9-21.
5. Lu P.Y., Woodle M.C. Delivering small interfering RNA for novel therapeutics. Methods Mol Biol 2008, 437:93-107.
6. De Paula D., Bentley M.V., Mahato R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13:431-456.
7. Sah D.W.Y. Therapeutic potential of RNA interference for neurological disorders. Life Sci 2006, 79:1773-1780.
8. Reischl D., Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomed Nanotech Biol Med 2009, 5:8-20.
9. Oh Y.K., Park T.G. SiRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009, 61:850-862.
10. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., et al. Position specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
11. Fougerolles A.D., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
12. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
13. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2:711-719.
14. White P.J. Barriers to successful delivery of short interfering rna after systemic administration. Clin Experim Pharm & Physiol 2008, 35:1371-1376.
15. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007, 117:3623-3632.
16. Allen T.M., Stuart D.D. Liposomes pharmacokinetics. Liposomes rational design 1999, 63. Marcel Dekker, Inc, New York, Basel. A.S. Janoff (Ed.).
17. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-743.
18. Guo P., Coban O., Snead N.M., Trebley J., Hoeprich S., Guo S., et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010, 62:650-666.
19. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008, 68:1247-1250.
20. Zheng X., Vladau C., Zhang X., Suzuki M., Ichim T.E., Zhang Z.X., et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009, 113:2646-2654.
21. Rothdiener M., Muller D., Castro P.G., Scholz A., Schwemmlein M., Fey G., et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Rel 2010, 144:251-258.
22. Wang W., Tang N., Zhang C.L., Liu X.J., Hu H., Zhang Z.X., et al. Cell penetrating peptides enhance intracellular translocation and function of siRNA encapsulated in PEGylated liposomes. Yao Xue Xue Bao 2006, 41:142-148.
23. Sorensen D.R., Leirdal M., Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003, 327:761-766.
24. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006, 13:1222-1234.
25. Lavigne C., Thierry A.R. Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells. Biochimie 2007, 89:1245-1251.
26. Shim G., Han S.E., Yu Y.H., Lee S., Lee H.Y., Kim K., et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Rel 2011, 155:60-66.
27. Ling V. Multidrug resistance and P-glycoprotein expression. Ann NY Acad Sci 1987, 507:7-8.
28. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994, 13:223-233.
29. Jiang J., Yang S.J., Wang J.C., Yang L.J., Xu Z., Yang T., et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010, 76:170-178.
30. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32:3459-3470.
31. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
32. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
33. Halder J., Kamat A.A., Landen C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006, 12:4916-4924.
34. Gray M.J., Van Buren G., Dallas N.A., Xia L., Wang X., Yang A.D., et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 2008, 100:109-120.
35. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372.
36. Bedi D. Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomed Nanotech Biol Med 2011, 7:315-323.
37. Bhadra D., Bhadra S., Jain P., Jain N.K. Pegnology: a review of PEG-ylated systems. Pharmazie 2002, 57:5-29.
38. Jain K.K. The role of nanobiotechnology in drug discovery. Drug Discov Today 2005, 10:1435-1442.
39. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci 2005, 102:9469-9474.
40. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Rel 2006, 116:123-129.
41. Li W., Szoka F. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007, 24:438-449.
42. Liu H., Guo S., Roll R., Li J., Diao Z., Shao N., et al. Phi29 pRNA Vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther 2007, 6:697-704.
43. Tanaka T., Shivamoto S., Miyashita M., Fujishima Y., Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004, 277:39-61.
44. Iyer A.K., Greish K., Seki T., Okazaki S., Fang J., Takeshita K., et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target 2007, 15:496-506.
45. Khaled A., Guo S., Li F., Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 2005, 5:1797-1808.
46. Zhang H.M., Su M.Y., Guo S., Yuan J., Lim T., Liu J., et al. Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antivir Res 2009, 83:307-316.
47. Yoshizawa T., Hattori Y., Hakoshima M., Koga K., Maitani Y. Folate-linked lipid based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008, 70:718-725.
48. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
49. Kenny G.D., Kamaly N., Kalber T.L., Brody L.P., Sahuri M., Shamsaei E., et al. Novel multifunctional nanoparticle mediates siRNA tumor delivery, visualization and therapeutic tumor reduction in vivo. J Control Rel 2011, 149:111-116.
50. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000, 65:271-284.
51. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
52. Li S.D., Chono S., Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Rel 2008, 126:77-84.
53. Ito T., Iida-Tanaka N., Niidome T., Kawano T., Kubo K., Yoshikawa K., et al. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J Control Rel 2006, 112:382-388.
54. Peppas L.B., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649-1659.
55. Chono S., Li S.D., Conwell C.C., Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Rel 2008, 131:64-69.
56. Li S.D., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006, 3:579-588.
57. Sokolova V., Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl 2008, 47:1382-1395.
58. Bisht S., Bhakta G., Mitra S., Maitra A. pDNA loaded calciumphosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharm 2005, 288:157-168.
59. Li J., Chen Y.C., Tseng Y.C., Mozumdar S., Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Rel 2010, 142:416-421.
60. Huh M.S., Lee S.Y., Park S., Lee S., Chung H., Lee S., et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Rel 2010, 144:134-143.
61. Martimprey H., Ito E., Akita H., Oishi M., Nagasaki Y., Futaki S., et al. SiRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res 2008, 36:e2.
62. Pille J.Y., Li H., Blot E., Bertrand J.R., Pritchard L.L., Opolon P., et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006, 17:1019-1026.
63. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28:1565-1571.
64. Hatakeyama H., Ito E., Akita H., Oishi M., Nagasaki Y., Futaki S., et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Rel 2010, 139:127-132.
65. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm 2008, 5:622-631.
66. Kesharwani P., Tekade R.K., Gajbhiye V., Jain K., Jain N.K. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed Nanotech Biol Med 2011, 7:295-304.
67. Liu M., Kono K., Frechet J.M. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Rel 2000, 65:121-131.
68. Twyman L.J., Beezer A.E., Esfand R., Hardy M.J., Mitchell J.C. The synthesis of water soluble dendrimers, and their application as possible drug delivery systems. Tetrahedron Lett 1999, 40:1743-1746.
69. Latallo K.J.F., Raczka E., Quintana A., Chen C.L., Rymaszewski M., Baker J.R. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther 2000, 11:1385-1395.
70. Gupta U., Agashe H.B., Jain N.K. Poly (propylene imine) dendrimer mediated solubility enhancement, effect of pH and functional groups of hydrophobes. J Pharm Sci 2007, 10:358-367.
71. Fischer M., Vogtle F. Dendrimers: from design to application-A progress report. Angew Chem Int Edn Engl 1999, 38:884.
72. Gillies E.R., Dy E., Frechet J.M., Szoka F.C. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm 2005, 2:129-138.
73. Haensler J., Szoka F.C. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993, 4:372-379.
74. Taratula O., Garbuzenko O.B., Kirkpatrick P., Pandya I., Savla R., Pozharov V.P., et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Rel 2009, 140:284-293.
75. Oupicky D., Carlisle R.C., Seymour R.C. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther 2001, 8:713-724.
76. Dutta T., Garg M., Jain N.K. Poly (propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B. Vaccine 2008, 26:3389-3394.
77. Tomalia D.A., Naylor A.M., Goddard W.A. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 1990, 29:138-175.
78. Bhadra D., Bhadra S., Jain S., Jain N.K. PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003, 257:111-124.
79. Dutta T., Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007, 1770:681-686.
80. Patil M.L., Zhang M., Taratula O., Garbuzenko O.B., He H., Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009, 9:258-266.
81. Franco E.L., Schlecht N.F., Saslow D. The epidemiology of cervical cancer. Cancer 2006, 9:348-359.
82. DiPaolo J.A., Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin Biol Ther 2004, 4:1251-1264.
83. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000, The global picture. Eur J Cancer 2001, 37:S4-S66.
84. Dutta T., Burgess M., McMillan N.A.J., Parekh H.S. Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomed Nanotech Biol Med 2010, 6:463-470.
85. Chen A.M., Santhakumaran L.M., Nair S.K., Amenta P.S., Thomas T., He H., et al. Oligonucleotide nanostructure formation in the presence of polypropyleneimine dendrimers and their uptake in breast cancer cells. Nanotechnology 2006, 17:5449-5460.
86. Patil M.L., Zhang M., Minko T. Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano 2011, 22:1877-1887.
87. Patil M.L. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008, 19:1396-1403.
88. Agrawal A., Min D.H., Singh N., Zhu H., Birjiniuk A., Maltzahn G.V., et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009, 3:2495-2504.
89. Ortega P., Bermejo J.F., Chonco L., de Jesus E., de laMata F.J., Fernandez G., et al. Novel water soluble carbosilane dendrimers: synthesis and biocompatibility. Eur J Inorg Chem 2006, 7:1388-1396.
90. Weber N., Ortega P., Clemente M.I., Shcharbin D., Bryszewska M., Mata F.J., et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J Control Rel 2008, 132:55-64.
91. Posadas I., Lopez-Hernandez B., Clemente M.I., Jimenez J.L., Ortega P., de la Mata J., et al. Highly efficient transfection of rat cortical neurons using carbosilane dendrimers unveils a neuroprotective role for HIF-1alpha in early chemical hypoxia-mediated neurotoxicity. Pharm Res 2009, 26:1181-1191.
92. Vlasov G.P. Starlike branched and hyperbranched biodegradable polymer systems as DNA carriers. Russ J Bioorg Chem 2006, 32:205-218.
93. Inoue Y., Kurihara R., Tsuchida A., Hasegawa M., Nagashima T., Mori T., et al. Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Rel 2008, 126:59-66.
94. Rey D.A., Batt C.A., Miller J.C. Carbon nanotubes in biomedical applications. Nanotech Law Busi 2006, 3:263-292.
95. Lacerda L., Bianaco A., Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev 2006, 58:1460-1470.
96. Bianco A., Kostarelos K., Partidos C.D., Prato M. Biomedical applications of functionalised CNTs. Chem Commun (Camb) 2005, 5:571-577.
97. Pantarotto D., Singh R., McCarthy D., Erhardt M., Briand J.P., Prato M., et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem Int Ed Engl 2004, 43:5242-5246.
98. Cai D., Mataraza J.M., Qin Z.H., Huang Z., Huang J., Chiles T.C., et al. Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat Methods 2005, 2:449-454.
99. Klumpp C., Kostarelos K., Prato M., Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta 2006, 1758:404-412.
100. Zhang Z.H., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006, 12:4933-4939.
101. Liu Z., Winters M., Holodniy M., Dai H. SiRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 2007, 46:2023-2027.
102. Wang X., Ren J., Qu X. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. Chem Med Chem 2008, 3:940-945.
103. Ladeira M.S., Andrade V.A., Gomes E.R.M., Aguiar C.J., Moraes E.R., Soares J.S., et al. Highly efficient siRNA delivery system into human and murine cells using single-wall carbon nanotubes. Nanotechnology 2010, 21:385101.
104. Al-Jamal P., Herrero K.T., Tian M.A., Ali-Boucetta B., Hegde H., Bianco V., et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009, 5:1176-1185.
105. Varkouhi A.K., Foillard S., Lammers T., Schiffelers R.M., Doris E., Hennink W.E., et al. SiRNA delivery with functionalized carbon nanotubes. Int J Pharm 2011, 416:419-425.
106. Krajcik R., Jung A., Hirsch A., Neuhuber W., Zolk O. Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes. Biochem Biophys Res Commun 2008, 369:595-602.